Latest news
Latest publications
- Nicol S, Trin K, Simon LA, Nowak E, Duval O, Martin C, Abdelouahad S, Lengagne S, Chinchilla V, Gilet V, Briantais A, Saraux A, Cornec D, De Moreuil C, Tanguy ML, Guellec D. Evaluation of a nurse-led program for the prevention of complications of long-term glucocorticoids (COCORTICO): study protocol for a randomized trial. Trials. 2025 Nov 17;26(1):510. PMCID: PMC12625073
- Hamroun S, de Frémont GM, Costedoat-Chalumeau N, Couderc M, Flipo RM, Sellam J, Richez C, Belkhir R, Gossec L, Marotte H, Dernis E, Frazier-Mironer A, Gervais E, Lukas C, Devauchelle-Pensec V, Deroux A, Guern VL, Guettrot-Imbert G, Lelong N, Pannier E, Sentilhes L, Ray CL, Seror R, Molto A, GR2 and the ENP2021 Study Groups. Evaluation of pregnancy outcomes in patients with spondyloarthritis compared to the general population: results from a French national prospective and matched study. Ann Rheum Dis. 2025 Nov 14;S0003-4967(25)04511-X. PMID: 41241656
- Autret L, Shipley É, Lodde B, Hinojosa-Azaola A, Saraux A. Rheumatic and musculoskeletal disorders in musicians: risks, adaptations and management. RMD Open. 2025 Oct 13;11(4):e006149. PMCID: PMC12519710
- Tison A, Bass AR. What can imaging teach us about immune checkpoint inhibitor-induced arthritis? Lancet Rheumatol. 2025 Oct;7(10):e663–e664. PMID: 40513595
- St Clair EW, Baer AN, Ng WF, Noaiseh G, Tarrant TK, Papas A, Devauchelle-Pensec V, Alevizos I, Baldini C. Plain language summary: treatment of Sjögren’s disease with dazodalibep. Immunotherapy. 2025 Oct;17(15):1063–1077. PMCID: PMC12607290
The UMR1227 'B Lymphocytes and Autoimmunity' brings together several clinical entities around the immunology laboratory.
Rheumatology, haematology, nephorology and odontology for a scientific project articulated around two main complementary and interconnected axes: an axis dedicated to the understanding of the mechanisms that govern the functional orientation of B cells in autoimmunity, and a translational axis aiming at developing new tools to improve the efficiency of B-cell targeting immunotherapies, while working on a better stratification of patients, a better understanding of the mode of action of these therapies, and the development of these therapies and innovative therapeutic strategies.
Key figures
They support us
